Covaxin’s scientific standards & commitment is transparent: BharatBio JMD Suchitra Ella

By: |
June 12, 2021 6:12 PM

The complete data for Phase I and II, and partial data for Phase III trials of Covaxin have been thoroughly scrutinised by the regulators in India, Bharat Biotech said in a statement.

Suchitra Ella said the data of Phase 3 trials has been submitted to the Drug Controller General of India for its perusal and efficacy of the vaccine against many of the coronavirus variants was also tested.Suchitra Ella said the data of Phase 3 trials has been submitted to the Drug Controller General of India for its perusal and efficacy of the vaccine against many of the coronavirus variants was also tested.

Bharat Biotech on Saturday said scientific standards and commitment of the indigenously-developed COVID-19 vaccine Covaxin are transparent, and the company has so far published nine research studies on its safety and efficacy.

“Covaxin’s scientific standards+commitment is transparent. Academic journals, peer reviewers, NIV-ICMR-BB researchers -scientists,9 studys & data published,” BharatBiotech CoFounder & Joint MD Suchitra Ella said in a tweet.

The complete data for Phase I and II, and partial data for Phase III trials of Covaxin have been thoroughly scrutinised by the regulators in India, Bharat Biotech said in a statement.

“In a timely approach to peer review, the company has already published as many as nine research studies on the safety and efficacy of Covaxin in five globally reputed peer-reviewed journals in a span of just twelve months,” it added.

Covaxin, a whole-virion inactivated coronavirus vaccine, is the first and only product to have published any data from human clinical trials in India, Bharat Biotech said.

“It is the only product to have any data on emerging variants. It is also the first and only COVID-19 vaccine to have efficacy data in Indian populations,” it added.

Bharat Biotech completed three preclinical studies, which are published in Cellpress, a peer-reviewed journal. The studies on Covaxin’s Phase I and Phase II clinical trial are published by the peer-reviewed journal, The Lancet – Infectious Diseases, Bharat Biotech said.

The full data from studies on Covaxin’s neutralisation of variants are already published at bioRxiv, Clinical Infectious Diseases, and Journal of Travel Medicine, it added.

“Currently, data from both efficacy and safety follow-up of Covaxin’s Phase III trial is being analysed and compiled. Upholding its uncompromising commitment to integrity, the company will make Phase III trials data from the final analysis public soon,” Bharat Biotech said.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Coronavirus did leak from China’s Wuhan Institute of Virology, claims explosive report by US Republicans
2Department of physiotherapy at DPSRU launches pediatrics physiotherapy unit
3Over 3.14 crore Covid vaccine doses available with states, UTs and pvt hospitals: Govt